LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 48

Search options

  1. Article ; Online: Developing the EAVE III platform for future health crises.

    Simpson, Colin R / Robertson, Chris / McMenamin, Jim / Ritchie, Lewis D / Sheikh, Aziz

    The Lancet. Infectious diseases

    2023  Volume 23, Issue 11, Page(s) 1223–1225

    MeSH term(s) Animals ; Humans ; Anopheles ; Insecticides
    Chemical Substances Insecticides
    Language English
    Publishing date 2023-10-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(23)00626-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Caveats in reporting of national vaccine uptake.

    Millington, Tristan / Morrison, Kirsty / Jeffrey, Karen / Sullivan, Christopher / Kurdi, Amanj / Fagbamigbe, Adeniyi Francis / Swallow, Ben / Shi, Ting / Shah, Syed Ahmar / Kerr, Steven / Simpson, Colin R / Ritchie, Lewis D / Robertson, Chris / Sheikh, Aziz / Rudan, Igor

    Journal of global health

    2024  Volume 14, Page(s) 3006

    MeSH term(s) Humans ; Influenza Vaccines ; Influenza, Human/prevention & control
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2024-02-09
    Publishing country Scotland
    Document type Journal Article
    ZDB-ID 2741629-X
    ISSN 2047-2986 ; 2047-2986
    ISSN (online) 2047-2986
    ISSN 2047-2986
    DOI 10.7189/jogh.14.03006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.

    Mackenzie, Isla S / Hawkey, Christopher J / Ford, Ian / Greenlaw, Nicola / Pigazzani, Filippo / Rogers, Amy / Struthers, Allan D / Begg, Alan G / Wei, Li / Avery, Anthony J / Taggar, Jaspal S / Walker, Andrew / Duce, Suzanne L / Barr, Rebecca J / Dumbleton, Jennifer S / Rooke, Evelien D / Townend, Jonathan N / Ritchie, Lewis D / MacDonald, Thomas M

    Health technology assessment (Winchester, England)

    2024  Volume 28, Issue 18, Page(s) 1–55

    Abstract: Background: Allopurinol is a xanthine oxidase inhibitor that lowers serum uric acid and is used to prevent acute gout flares in patients with gout. Observational and small interventional studies have suggested beneficial cardiovascular effects of ... ...

    Abstract Background: Allopurinol is a xanthine oxidase inhibitor that lowers serum uric acid and is used to prevent acute gout flares in patients with gout. Observational and small interventional studies have suggested beneficial cardiovascular effects of allopurinol.
    Objective: To determine whether allopurinol improves major cardiovascular outcomes in patients with ischaemic heart disease.
    Design: Prospective, randomised, open-label, blinded endpoint multicentre clinical trial.
    Setting: Four hundred and twenty-four UK primary care practices.
    Participants: Aged 60 years and over with ischaemic heart disease but no gout.
    Interventions: Participants were randomised (1 : 1) using a central web-based randomisation system to receive allopurinol up to 600 mg daily that was added to usual care or to continue usual care.
    Main outcome measures: The primary outcome was the composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Secondary outcomes were non-fatal myocardial infarction, non-fatal stroke, cardiovascular death, all-cause mortality, hospitalisation for heart failure, hospitalisation for acute coronary syndrome, coronary revascularisation, hospitalisation for acute coronary syndrome or coronary revascularisation, all cardiovascular hospitalisations, quality of life and cost-effectiveness. The hazard ratio (allopurinol vs. usual care) in a Cox proportional hazards model was assessed for superiority in a modified intention-to-treat analysis.
    Results: From 7 February 2014 to 2 October 2017, 5937 participants were enrolled and randomised to the allopurinol arm (
    Limitations: The results may not be generalisable to younger populations, other ethnic groups or patients with more acute ischaemic heart disease. One thousand six hundred and thirty-seven participants (57.4%) in the allopurinol arm withdrew from randomised treatment, but an on-treatment analysis gave similar results to the main analysis.
    Conclusions: The ALL-HEART study showed that treatment with allopurinol 600 mg daily did not improve cardiovascular outcomes compared to usual care in patients with ischaemic heart disease. We conclude that allopurinol should not be recommended for the secondary prevention of cardiovascular events in patients with ischaemic heart disease but no gout.
    Future work: The effects of allopurinol on cardiovascular outcomes in patients with ischaemic heart disease and co-existing hyperuricaemia or clinical gout could be explored in future studies.
    Trial registration: This trial is registered as EU Clinical Trials Register (EudraCT 2013-003559-39) and ISRCTN (ISRCTN 32017426).
    Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 11/36/41) and is published in full in
    MeSH term(s) Humans ; Male ; Middle Aged ; Aged ; Female ; Allopurinol/therapeutic use ; Cost-Benefit Analysis ; Acute Coronary Syndrome ; Quality of Life ; Prospective Studies ; Uric Acid ; Myocardial Ischemia/drug therapy ; Gout/drug therapy ; Stroke/drug therapy ; Myocardial Infarction/drug therapy
    Chemical Substances Allopurinol (63CZ7GJN5I) ; Uric Acid (268B43MJ25)
    Language English
    Publishing date 2024-03-29
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 2006765-3
    ISSN 2046-4924 ; 1366-5278
    ISSN (online) 2046-4924
    ISSN 1366-5278
    DOI 10.3310/ATTM4092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.

    Shah, Syed Ahmar / Robertson, Chris / Rudan, Igor / Murray, Josephine Lk / McCowan, Colin / Grange, Zoe / Buelo, Audrey / Sullivan, Christopher / Simpson, Colin R / Ritchie, Lewis D / Sheikh, Aziz

    Journal of global health

    2022  Volume 12, Page(s) 5008

    Abstract: Background: The emergence of the B.1.617.2 Delta variant of concern was associated with increasing numbers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and COVID-19 hospital admissions. We aim to study national population ... ...

    Abstract Background: The emergence of the B.1.617.2 Delta variant of concern was associated with increasing numbers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and COVID-19 hospital admissions. We aim to study national population level SARS-CoV-2 infections and COVID-19 associated hospitalisations by vaccination status to provide insight into the association of vaccination on temporal trends during the time in which the SARS-CoV-2 Delta variant became dominant in Scotland.
    Methods: We used the Scotland-wide Early Pandemic Evaluation and Enhanced Surveillance (EAVE II) platform, covering the period when Delta was pervasive (May 01 to October 23, 2021). We performed a cohort analysis of every vaccine-eligible individual aged 20 or over from across Scotland. We determined the vaccination coverage, SARS-CoV-2 incidence rate and COVID-19 associated hospitalisations incidence rate. We then stratified those rates by age group, vaccination status (defined as "unvaccinated", "partially vaccinated" (1 dose), or "fully vaccinated" (2 doses)), vaccine type (BNT162b2 or ChAdOx1 nCoV-19), and coexisting conditions known to be associated with severe COVID-19 outcomes.
    Results: During the follow-up of 4 183 022 individuals, there were 407 405 SARS-CoV-2 positive cases with 10 441 (2.6%) associated with a hospital admission. Those vaccinated with two doses (defined as fully vaccinated in the current study) of either vaccine had lower incidence rates of SARS-CoV-2 infections and much lower incidence rates of COVID-19 associated hospitalisations than those unvaccinated in the Delta era in Scotland. Younger age groups were substantially more likely to get infected. In contrast, older age groups were much more likely to be hospitalised. The incidence rates stratified by coexisting conditions were broadly comparable with the overall age group patterns.
    Conclusions: This study suggests that national population level vaccination was associated with a reduction in SARS-CoV-2 infections and COVID-19 associated hospitalisation in Scotland throughout the Delta era.
    MeSH term(s) Adult ; Aged ; BNT162 Vaccine ; COVID-19/epidemiology ; COVID-19/prevention & control ; ChAdOx1 nCoV-19 ; Hospitalization ; Humans ; Incidence ; SARS-CoV-2 ; Vaccination ; Viral Vaccines ; Young Adult
    Chemical Substances Viral Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8) ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-03-26
    Publishing country Scotland
    Document type Journal Article
    ZDB-ID 2741629-X
    ISSN 2047-2986 ; 2047-2986
    ISSN (online) 2047-2986
    ISSN 2047-2986
    DOI 10.7189/jogh.12.05008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Characterising adults in Scotland who are not vaccinated against COVID-19.

    Hameed, Safraj Shahul / Hall, Elliott / Grange, Zoe / Sullivan, Christopher / Kennedy, Sharon / Ritchie, Lewis D / Agrawal, Utkarsh / Simpson, Colin R / Shah, Syed Ahmar / Rudan, Igor / McCowan, Colin / Murray, Josephine L K / Robertson, Chris / Sheikh, Aziz

    Lancet (London, England)

    2022  Volume 400, Issue 10357, Page(s) 993–995

    MeSH term(s) Adult ; COVID-19/prevention & control ; Humans ; Scotland/epidemiology ; Vaccination
    Language English
    Publishing date 2022-09-24
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(22)01653-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

    Simpson, Colin R / Kerr, Steven / Katikireddi, Srinivasa Vittal / McCowan, Colin / Ritchie, Lewis D / Pan, Jiafeng / Stock, Sarah J / Rudan, Igor / Tsang, Ruby S M / de Lusignan, Simon / Hobbs, F D Richard / Akbari, Ashley / Lyons, Ronan A / Robertson, Chris / Sheikh, Aziz

    Nature communications

    2022  Volume 13, Issue 1, Page(s) 4800

    Abstract: We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two ... ...

    Abstract We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2. The incidence rate ratio (IRR) for idiopathic thrombocytopenic purpura (ITP) 14-20 days post-ChAdOx1 second dose was 2.14, 95% confidence interval (CI) 0.90-5.08. The incidence of ITP post-second dose ChAdOx1 was 0.59 (0.37-0.89) per 100,000 doses. No evidence of an increased risk of CVST was found for the 0-27 day risk period (IRR 0.83, 95% CI 0.16 to 4.26). However, few (≤5) events arose within this risk period. It is perhaps noteworthy that these events all clustered in the 7-13 day period (IRR 4.06, 95% CI 0.94 to 17.51). No other associations were found for second dose ChAdOx1, or any association for second dose BNT162b2 vaccination. Second dose ChAdOx1 vaccination was associated with increased borderline risks of ITP and CVST events. However, these events were rare thus providing reassurance about the safety of these vaccines. Further analyses including more cases are required to determine more precisely the risk profile for ITP and CVST after a second dose of ChAdOx1 vaccine.
    MeSH term(s) Adult ; BNT162 Vaccine/adverse effects ; COVID-19/epidemiology ; COVID-19/prevention & control ; ChAdOx1 nCoV-19/adverse effects ; Humans ; Prospective Studies ; Purpura, Thrombocytopenic, Idiopathic/chemically induced ; Purpura, Thrombocytopenic, Idiopathic/epidemiology ; Scotland ; Thromboembolism/chemically induced ; Thromboembolism/epidemiology ; Vaccination/adverse effects
    Chemical Substances ChAdOx1 nCoV-19 (B5S3K2V0G8) ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2022-08-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-022-32264-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Predicted COVID-19 positive cases, hospitalisations, and deaths associated with the Delta variant of concern, June-July, 2021.

    Shah, Syed Ahmar / Moore, Emily / Robertson, Chris / McMenamin, Jim / Katikireddi, Srinivasa Vittal / Simpson, Colin R / Shi, Ting / Agrawal, Uktarsh / McCowan, Colin / Stock, Sarah / Ritchie, Lewis D / Sheikh, Aziz

    The Lancet. Digital health

    2021  Volume 3, Issue 9, Page(s) e539–e541

    MeSH term(s) COVID-19/mortality ; COVID-19/therapy ; COVID-19/virology ; Female ; Hospital Mortality ; Hospitalization ; Humans ; Male ; Models, Biological ; Pandemics ; Proportional Hazards Models ; SARS-CoV-2 ; Severity of Illness Index
    Language English
    Publishing date 2021-08-09
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2589-7500
    ISSN (online) 2589-7500
    DOI 10.1016/S2589-7500(21)00175-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study.

    Simpson, Colin R / Robertson, Chris / Vasileiou, Eleftheria / Moore, Emily / McCowan, Colin / Agrawal, Utkarsh / Stagg, Helen R / Docherty, Annemarie / Mulholland, Rachel / Murray, Josephine L K / Ritchie, Lewis D / McMenamin, Jim / Sheikh, Aziz

    The Lancet. Digital health

    2021  Volume 3, Issue 8, Page(s) e517–e525

    Abstract: Background: As the COVID-19 pandemic continues, national-level surveillance platforms with real-time individual person-level data are required to monitor and predict the epidemiological and clinical profile of COVID-19 and inform public health policy. ... ...

    Abstract Background: As the COVID-19 pandemic continues, national-level surveillance platforms with real-time individual person-level data are required to monitor and predict the epidemiological and clinical profile of COVID-19 and inform public health policy. We aimed to create a national dataset of patient-level data in Scotland to identify temporal trends and COVID-19 risk factors, and to develop a novel statistical prediction model to forecast COVID-19-related deaths and hospitalisations during the second wave.
    Methods: We established a surveillance platform to monitor COVID-19 temporal trends using person-level primary care data (including age, sex, socioeconomic status, urban or rural residence, care home residence, and clinical risk factors) linked to data on SARS-CoV-2 RT-PCR tests, hospitalisations, and deaths for all individuals resident in Scotland who were registered with a general practice on Feb 23, 2020. A Cox proportional hazards model was used to estimate the association between clinical risk groups and time to hospitalisation and death. A survival prediction model derived from data from March 1 to June 23, 2020, was created to forecast hospital admissions and deaths from October to December, 2020. We fitted a generalised additive spline model to daily SARS-CoV-2 cases over the previous 10 weeks and used this to create a 28-day forecast of the number of daily cases. The age and risk group pattern of cases in the previous 3 weeks was then used to select a stratified sample of individuals from our cohort who had not previously tested positive, with future cases in each group sampled from a multinomial distribution. We then used their patient characteristics (including age, sex, comorbidities, and socioeconomic status) to predict their probability of hospitalisation or death.
    Findings: Our cohort included 5 384 819 people, representing 98·6% of the entire estimated population residing in Scotland during 2020. Hospitalisation and death among those testing positive for SARS-CoV-2 between March 1 and June 23, 2020, were associated with several patient characteristics, including male sex (hospitalisation hazard ratio [HR] 1·47, 95% CI 1·38-1·57; death HR 1·62, 1·49-1·76) and various comorbidities, with the highest hospitalisation HR found for transplantation (4·53, 1·87-10·98) and the highest death HR for myoneural disease (2·33, 1·46-3·71). For those testing positive, there were decreasing temporal trends in hospitalisation and death rates. The proportion of positive tests among older age groups (>40 years) and those with at-risk comorbidities increased during October, 2020. On Nov 10, 2020, the projected number of hospitalisations for Dec 8, 2020 (28 days later) was 90 per day (95% prediction interval 55-125) and the projected number of deaths was 21 per day (12-29).
    Interpretation: The estimated incidence of SARS-CoV-2 infection based on positive tests recorded in this unique data resource has provided forecasts of hospitalisation and death rates for the whole of Scotland. These findings were used by the Scottish Government to inform their response to reduce COVID-19-related morbidity and mortality.
    Funding: Medical Research Council, National Institute for Health Research Health Technology Assessment Programme, UK Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, Scottish Government Director General Health and Social Care.
    MeSH term(s) Adolescent ; Adult ; Aged ; COVID-19/epidemiology ; COVID-19/mortality ; COVID-19 Nucleic Acid Testing/statistics & numerical data ; COVID-19 Nucleic Acid Testing/trends ; Child ; Child, Preschool ; Comorbidity/trends ; Female ; Forecasting ; Hospitalization ; Humans ; Incidence ; Infant ; Infant, Newborn ; Information Storage and Retrieval ; Male ; Middle Aged ; Models, Statistical ; Primary Health Care/statistics & numerical data ; Risk Factors ; Scotland/epidemiology ; Sex Factors
    Language English
    Publishing date 2021-07-05
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2589-7500
    ISSN (online) 2589-7500
    DOI 10.1016/S2589-7500(21)00105-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Investigating the public's use of Scotland's primary care telephone advice service (NHS 24): a population-based cross-sectional study.

    McAteer, Anne / Hannaford, Philip C / Heaney, David / Ritchie, Lewis D / Elliott, Alison M

    The British journal of general practice : the journal of the Royal College of General Practitioners

    2016  Volume 66, Issue 646, Page(s) e337–46

    Abstract: Background: There has been no comprehensive examination of the public's understanding of, and attitudes towards, NHS 24.: Aim: To investigate the public's use of NHS 24 and explore their understanding of, and beliefs about, the service.: Design and ...

    Abstract Background: There has been no comprehensive examination of the public's understanding of, and attitudes towards, NHS 24.
    Aim: To investigate the public's use of NHS 24 and explore their understanding of, and beliefs about, the service.
    Design and setting: Population-based cross-sectional study of adults in Scotland.
    Method: Quantitative data were collected by self-completion postal questionnaire and qualitative data by follow-up telephone interviews.
    Results: A corrected response rate of 34.1% (n = 1190) was obtained. More than half (51.0%, n = 601) of responders had used NHS 24. Callers were more likely to be female, have at least one child, and be aged 25-34 years. Most calls (92.4%, n = 549) were made out of hours, and 54.6% (n = 327) were made on behalf of someone else. The main reason for calling was to get advice about a new symptom (69.0%, n = 414). A total of 38.6% (n = 219) of users contacted another health professional following their call, mostly on NHS 24 advice (71.7%, n = 157). Over 80.0% (n = 449) of callers were satisfied with the service and 93.9% (n = 539) would use it again.Only 8.4% (n = 78) of responders had used the NHS 24 website and 4.6% (n = 53) the NHS inform service. The main reasons for non-use were not needing the service, a preference to see their own GP, and not knowing the telephone number. NHS 24 was mainly viewed as an out-of-hours alternative to the GP. It was not considered an appropriate service for minor symptoms. The main facilitator to use was convenience, whereas the main barrier to use was not knowing how and when to use the service.
    Conclusion: Although most people who used NHS 24 were satisfied, others were unclear about how and when to use the service. Further education about the full range of services that NHS 24 offers should be considered.
    MeSH term(s) After-Hours Care/statistics & numerical data ; Cross-Sectional Studies ; Health Services Accessibility/statistics & numerical data ; Health Services Research ; Hotlines ; Humans ; Patient Acceptance of Health Care/statistics & numerical data ; Patient Satisfaction ; Primary Health Care/statistics & numerical data ; Program Evaluation ; Qualitative Research ; Scotland/epidemiology ; State Medicine ; Surveys and Questionnaires ; Telephone ; Time Factors ; Triage/standards
    Language English
    Publishing date 2016-03-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 1043148-2
    ISSN 1478-5242 ; 0035-8797 ; 0960-1643
    ISSN (online) 1478-5242
    ISSN 0035-8797 ; 0960-1643
    DOI 10.3399/bjgp16X684409
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data.

    Simpson, Colin R / Robertson, Chris / Vasileiou, Eleftheria / McMenamin, Jim / Gunson, Rory / Ritchie, Lewis D / Woolhouse, Mark / Morrice, Lynn / Kelly, Dave / Stagg, Helen R / Marques, Diogo / Murray, Josie / Sheikh, Aziz

    BMJ open

    2020  Volume 10, Issue 6, Page(s) e039097

    Abstract: Introduction: Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19 pandemic, population-level surveillance and rapid assessment of the effectiveness of existing or ... ...

    Abstract Introduction: Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19 pandemic, population-level surveillance and rapid assessment of the effectiveness of existing or new therapeutic or preventive interventions are required to ensure that interventions are targeted to those at highest risk of serious illness or death from COVID-19. We aim to repurpose and expand an existing pandemic reporting platform to determine the attack rate of SARS-CoV-2, the uptake and effectiveness of any new pandemic vaccine (once available) and any protective effect conferred by existing or new antimicrobial drugs and other therapies.
    Methods and analysis: A prospective observational cohort will be used to monitor daily/weekly the progress of the COVID-19 epidemic and to evaluate the effectiveness of therapeutic interventions in approximately 5.4 million individuals registered in general practices across Scotland. A national linked dataset of patient-level primary care data, out-of-hours, hospitalisation, mortality and laboratory data will be assembled. The primary outcomes will measure association between: (A) laboratory confirmed SARS-CoV-2 infection, morbidity and mortality, and demographic, socioeconomic and clinical population characteristics; and (B) healthcare burden of COVID-19 and demographic, socioeconomic and clinical population characteristics. The secondary outcomes will estimate: (A) the uptake (for vaccines only); (B) effectiveness; and (C) safety of new or existing therapies, vaccines and antimicrobials against SARS-CoV-2 infection. The association between population characteristics and primary outcomes will be assessed via multivariate logistic regression models. The effectiveness of therapies, vaccines and antimicrobials will be assessed from time-dependent Cox models or Poisson regression models. Self-controlled study designs will be explored to estimate the risk of therapeutic and prophylactic-related adverse events.
    Ethics and dissemination: We obtained approval from the National Research Ethics Service Committee, Southeast Scotland 02. The study findings will be presented at international conferences and published in peer-reviewed journals.
    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology ; Epidemiological Monitoring ; Humans ; Observational Studies as Topic ; Pandemics ; Patient Care Planning/organization & administration ; Pneumonia, Viral/epidemiology ; Prospective Studies ; Risk Assessment ; SARS-CoV-2 ; Scotland
    Keywords covid19
    Language English
    Publishing date 2020-06-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 2599832-8
    ISSN 2044-6055 ; 2044-6055
    ISSN (online) 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2020-039097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top